Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Myeloid 1

Conditions

Myeloproliferative Disorders 6Carcinoma, Non-Small-Cell Lung 5Primary Myelofibrosis 4Hematologic Neoplasms 4Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Hodgkin Disease 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Leukemia, Prolymphocytic, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2Thrombocytosis 1Solid Tumors 1Sarcoma, Synovial 1Sarcoma 1Polycythemia Vera 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma 1Liposarcoma, Myxoid 1Leukemia, Plasma Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

fludarabine phosphate 6Whole-Body Irradiation 5Mycophenolic Acid 5fludarabine 4Peripheral Blood Stem Cell Transplantation 4Cyclosporins 4Cyclosporine 4Cyclophosphamide 4venetoclax 3ruxolitinib 3Cytarabine 3Alemtuzumab 3itacitinib 2duvelisib 2carmustine, poliferprosan 20 drug combination 2Stem Cell Transplantation 2Sirolimus 2Melphalan 2Etoposide 2Carmustine 2thymoglobulin 1romidepsin 1niraparib 1nelarabine 1letermovir 1ibrutinib 1Tacrolimus 1Sensitivity and Specificity 1Mitoxantrone 1Lisaftoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, T-Cell × itacitinib × Clear all
NCT05823571 2025-09-18

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Active not recruiting
32 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Leukemia, Plasma Cell, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myelomonocytic, Chronic

NCT03989466 2024-10-10

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1 Completed
15 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡